Solulin

Solulin is a soluble recombinant analogue of human thrombomodulin developed by PAION Deutschland GmbH. It is an engineered biologic variant that lacks the transmembrane and cytoplasmic domains of endogenous thrombomodulin and contains specific directed mutations to enhance resistance to proteolysis and oxidation. Solulin acts as an anticoagulant by binding to free thrombin, which neutralizes thrombin's procoagulant activity (such as fibrinogen cleavage) and converts the enzyme into an activator of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI). This dual mechanism promotes systemic anticoagulation and modulates fibrinolysis. The drug has been primarily investigated for the treatment of acute ischemic stroke and other thrombotic diseases, having successfully completed Phase I clinical testing.

Brand names

Solulin

Other names

soluble recombinant human thrombomodulinsTM